Advanced Prostate Cancer Consensus Conference (APCCC)

In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, ...
read more ↘

 

PARP Inhibition (Dissected): Determining Who Benefits in mCRPC

31 views
November 5, 2024
Comments 0
Login to view comments. Click here to Login